Contact this trialFirst, we need to learn more about you.
PARP Inhibitor
Pembrolizumab + Olaparib for Breast Cancer
Recruiting1 awardPhase 2
Los Angeles, California
This trial will evaluate the use of immunotherapy and PARP inhibition to treat advanced breast cancer associated with a germline BRCA mutation or HDR-defect.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.